Mental Health Changes in US Transgender Adults Beginning Hormone Therapy Via Telehealth: Longitudinal Cohort Study

Изменения психического здоровья у трансгендерных взрослых в США, начинающих гормональную терапию посредством телемедицины: продольное когортное исследование
Michelle M. Forcier, Kellan Baker, Jaclyn M. W. Hughto, Janelle M. Downing, Theresa I. Shireman, Kate Steinle
2025-01-13

depression and anxietygender-affirming hormone therapysuicidal ideationtelehealthtransgender adults
BACKGROUND: Gender-affirming hormone therapy (GAHT) has shown potential for improving mental health outcomes among transgender and gender-diverse adults. How clinical outcomes change among adults receiving GAHT via telehealth across the United States is not well known. OBJECTIVE: This study evaluated the relationship between initiating GAHT via a telehealth clinic and changes in depression, anxiety, and suicide ideation over a 3-month period. METHODS: This cohort study evaluated the relationship between initiating GAHT via a telehealth clinic and changes in mental health over a 3-month period. Data were collected at baseline and 3 months later among adults who had their first GAHT visit between August and November 2023. The study included adults aged 18 years and older initiating GAHT for the first time, with a final sample of 342 adults across 43 states (192 initiated estrogen and 150 initiated testosterone therapy). The primary outcomes were depression symptoms using the Patient Health Questionnaire-9 (PHQ-9), anxiety symptoms using the General Anxiety Disorder-7 (GAD-7), and suicide ideation in the past 2 weeks. RESULTS: Before GAHT initiation, 40% (136/342) of participants reported depression (PHQ-9 ≥10), 36% (120/342) reported anxiety (GAD-7 ≥8), and 25% (91/342) reported suicidal ideation. By follow-up, significant reductions were observed in PHQ-9 (-2.4, 95% CI -3.0 to -1.8) and GAD-7 scores (-1.5, 95% CI -2.0 to -1.0). Among those with elevated symptoms, 40% (48/120) to 42% (56/133) achieved a clinically meaningful response (≥50% reduction in baseline scores), and 27% (36/133) to 28% (33/120) achieved remission (PHQ-9 or GAD-7 score <5). Of those with suicide ideation at baseline, 60% (50/83) had none at follow-up. CONCLUSIONS: This study highlights the important relationship between telehealth-delivered GAHT and mental health, emphasizing the importance of accessible and timely care.
1
After 3 months of GAHT, PHQ-9 depression scores decreased by 2.4 points and GAD-7 anxiety scores decreased by 1.5 points.
2
Among participants reporting suicidal ideation at baseline, 60% reported no suicidal ideation at 3-month follow-up.
3
Among participants with elevated baseline symptoms, 40%-42% achieved at least a 50% reduction in depression or anxiety scores.
4
At follow-up, 27%-28% of participants with elevated baseline symptoms met remission criteria for depression or anxiety.
5
In a 342-adult US cohort initiating GAHT via telehealth, baseline depression, anxiety, and suicidal ideation were reported by 40%, 36%, and 25% of participants, respectively.
6
The findings support an association between telehealth-delivered GAHT and improved short-term mental health outcomes, while not establishing causality.

US transgender and gender-diverse adults initiating gender-affirming hormone therapy via telehealth

Three-month changes in depression, anxiety, and suicidal ideation after initiating telehealth-delivered gender-affirming hormone therapy

Publication Details
Publication Date
2025-01-13
Journal
Publisher
ISSN
Cited by
3
Access Type
Author Information
Authors
Michelle M. Forcier
Kellan Baker
Jaclyn M. W. Hughto
Janelle M. Downing
Theresa I. Shireman
Kate Steinle
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%